Over the years various molecular subtypes for breast cancer have been defined as Luminal A, Luminal B, HER2-enriched, the basal-like and normal-like (Sørlie et al., 2001), which reflect to a large extent, immunohistochemistry-derived clinical categories (Belizario and Loggulo, 2019). This evidence concerns the gene ERBB2 and breast cancer.